transcend top-line
revenu slightli ahead pre-announc
expect margin improv focu us
pharmaci shift continu expand access price headwind
remain off-set volum ex-u continu
show strength top bottom line continu look
strength transcend top-line deliv revenu
vs mse note estim reflect number prior pre-
announc comment momentum deceler
pt us pt ou outsiz driven on-going shift pharmaci
increas insulin-depend type traction broad ex-u strength
momentum acceler pt overal volum
off-set price headwind year see greater detail
show slight upsid bp vs mse driven top-line om
deliv meaning beat driven pt sequenti sg
leverag mirror signific om leverag
shown histor pt pt exhibit result vs
thought guidanc top-line guidanc reiter
growth midpoint remain comfort growth model
reflect pt momentum deceler like
prove conserv upsid could driven increas volum
pharmaci driven lower price eas access estim pharmaci
compris us patient base note receiv
prefer statu caremark first time greater
penetr follow avail medicar channel unit
coverag april return dtc invest effort ramp
rais top-line growth guidanc pt averag
quarter believ manag set bar prudent
room rais margin guidanc om also appear
achiev proven abil drive om leverag pt
om expans commentari
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
deeper dive margin profit top-line strength clear
margin greater standout in-lin om pt
model similar top-line guidanc manag rais ebit guidanc
quarter throughout enter year recent
vs base trend believ guidanc could prove
conserv well
model bp gm expans vs bp
compress compani begin reap benefit
manufactur invest lesser extent move past
manufactur line issu resolv improv scale
like somewhat off-set manufactur ramp compani
prepar product launch year-end everi bp increment
gm expans would worth ep
oper expens leverag like continu ratio revenu growth
opex growth consist although
guidanc impli ratio closer acknowledg
invest prioriti expect step higher
launch sale dtc invest increase- off-set leverag
manila see room greater leverag anticip
revenu growth opex growth ratio in-lin would
reflect pt increment om expans ep adjust
 higher sg slightli lower reach revenu growth
opex growth impli increas y/i opex in-lin
bring us om previous
net inflect profit drive greater confid near-term
margin expans earn potenti answer one key question
stock
upcom catalyst see sever catalyst ahead includ
unitedhealth coverag decis expect april type intens
popul us non-intens type nearli japan
launch dtc effort potenti drive broader
adopt manag plan scale invest
import catalyst horizon remain track full global roll-out
clinic trial enrol sens even
robust trial rel lesser extent follow
attd next week expect see increment data integr
next-gen aid system tandem control-iq lilli see preview
focu gestat data annual us case
lrp continu look conserv pt although
maintain lrp guidanc sinc decemb analyst day sens
remain target revenu conserv
number impli compound-annual-growth-rate compani alreadi
deliv growth first year post-analyst day
indic confid abil produc cog product
reach scale view impli lrp margin guidanc
could also prove conserv continu model
revenu abbott libr deck see
competit remain import factor cgm still
meaning under-penetr continu see room dexcom
libr success mention disrupt form factor may
enabl penetr beyond insulin-intens diabet popul
analyt updat price target base ev sale
multipl rel in-lin high-growth devic peer
million except ep
mse number reflect estim prior pre-announc
sale
sale
sale
sale
price target reect ev sale multipl in-lin high growth
continu glucos monitor cgm
expos signic secular growth
expand type
type diabet us alon see
long runway cgm penetr grow
long term driven
product evolut improv form
factor integr insulin dose
accuraci eas use pharmaci
technolog leadership
sustain full launch
competit present price risk
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
feb gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
guardian libr traction limit
prove market expans premium price
sustain libr seen inferior
product success non-intens
pbm distribut drive clear path
om
revenu growth sustain
pressur price pressur larg
off-set volum shift
pharmaci integr system
type adopt rate
lower share price pressur limit
protabl guardian libr becom
competit core medicar
user libr disrupt price model
sensor price collaps cgm fail gain
traction non-intens popul
delay unabl drive gm expans
new patient larg pharmaci
channel sustain us growth europ
sustain technolog
leadership form factor/ integr
advantag competitor
china india
view explan region hierarchi
research highest favor quintil
libr delay beyond
launch ahead expect late
price headwind less anticip
guardian libr competit greater
expect limit new patient start
limit path protabl
delay failur pipelin catalyst
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
dollar million except per share data
dollar million except per share data
prepaid current asset
properti plant equip net
liabil equiti
account payabl accru liabil
accru payrol relat expens
current portion long-term debt
current portion defer revenu
long-term portion defer revenu
accumul comprehens loss
dollar million except per share data
oper
depreci amort
non-cash research develop issuanc common stock
accret amort relat market secur net
amort debt issuanc cost
chang fair valu conting consider
loss dispos equip
chang oper asset liabil
prepaid
account payabl accru liabil
accru payrol relat expens
defer rent liabil
net cash provid oper
invest
purchas available-for-sal market secur
proce matur available-for-sal market secur
purchas properti equip
acquisit net cash acquir
net cash use invest activ
financ
net proce issuanc common stock
issuanc repay debt
repurchas share
net cash use financ activ
begin period
end period
